BILL ANALYSIS                                                                                                                                                                                                    �



                                                                  AB 389
                                                                  Page  1

          CONCURRENCE IN SENATE AMENDMENTS
          AB 389 (Mitchell)
          As Amended  January 17, 2012
          Majority vote
           
           ----------------------------------------------------------------- 
          |ASSEMBLY:  |78-0 |(April 28,      |SENATE: |37-0 |(June 21,      |
          |           |     |2011)           |        |     |2012)          |
           ----------------------------------------------------------------- 
            
           Original Committee Reference:    B.,P. & C.P.  

           SUMMARY  :  Establishes requirements for providers of blood 
          clotting products for home use (providers) to treat hemophilia 
          and other bleeding disorders.  

           The Senate amendments  delete provisions related to home nursing 
          services and make technical changes.

           EXISTING LAW  :

          1)Specifies certain requirements regarding the proper storage, 
            handling, dispensing, and disposal of drugs, staff training 
            protocols, drug and supply inventory, labeling, and 
            maintenance of patient confidentiality.

          2)Allows pharmacists to perform certain procedures under 
            specified conditions, including, among other things, 
            administering drugs and biologics, such as blood clotting 
            products, by injection, pursuant to a prescriber's order.

          3)Establishes the Genetically Handicapped Persons Program, 
            administered by the Department of Health Care Services, to 
            provide for the medical care of adults with certain genetic 
            diseases, including hemophilia.

          4)Establishes the federal Food and Drug Administration to 
            regulate the manufacture of pharmaceuticals derived from blood 
            and blood components, such as blood clotting products, 
            including establishing standards for those products for 
            shipping, storage, and delivery, inspecting products, 
            approving products for use by patients, and recalling products 
            that may be defective or potentially harmful.

           AS PASSED BY THE ASSEMBLY  , this bill was substantially similar 








                                                                  AB 389
                                                                  Page  2

          to the version approved by the Senate.
           
          FISCAL EFFECT  :  According to the Senate Appropriations 
          Committee, pursuant to Senate Rule 28.8, negligible state costs. 

           

          Analysis Prepared by  :    Rebecca May / B.,P. & C.P. / (916) 
          319-3301 


                                                               FN: 0003016